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ABSTRACT
Bronchial asthma, characterized by chronic airway
inflammation, involves many inflammatory cytokines.
Interleukin (IL)-10 is a potent inhibitor of cytokine syn-
thesis. Thus, the effects of IL-10 were examined on the
production of granulocyte–macrophage colony stimu-
lating factor (GM-CSF), IL-5, IL-1 b , IL-2 and interferon
(IFN)-g by antigen (Dermatophagoides farinae, Df)-
stimulated mononuclear cells obtained from asthmatic
patients who were sensitized with the antigen and from
healthy subjects in vitro. Production of IL-5 and IL-2
was enhanced by Df antigen in the asthmatic subjects,
but not in the healthy controls. In contrast, levels of
GM-CSF, IFN-g and IL-1b production were enhanced
by the antigen in both groups. Exogenous IL-10 
(10 ng/mL) inhibited the production of GM-CSF, IFN-g
and IL-1b induced by Df antigen in both groups and
also inhibited the production of IL-5 and IL-2 induced
by the antigen in the asthmatics subjects. The inhibition
of GM-CSF production by IL-10 was stronger than that
by IL-4. These results indicated that the responsiveness
to the inhibitory effect of IL-10 on the production of
inflammatory cytokines is not abrogated in asthmatic
patients and that IL-10 may be useful in the treatment
of bronchial asthma.
Key words: bronchial asthma, granulocyte–macrophage
colony stimulating factor, interferon-g , interleukin-1b ,
interleukin-2, interleukin-5, interleukin-10.
INTRODUCTION
Bronchial asthma is characterized by chronic airway
inflammation, a process involving many inflammatory
cell types, such as mast cells, eosinophils, neutrophils,
lymphocytes and macrophages.1–3 These cells modulate
inflammation by producing cytokines at the sites of airway
inflammation.4–8 Investigation of bronchoalveolar lavage
fluid in asthmatic patients has revealed that levels 
of granulocyte–macrophage colony stimulating factor 
(GM-CSF), interleukin (IL)-5, IL-2 and IL-1b are higher in
the patients compared with non-asthmatic controls.9–11
Therefore, regulation of the production of inflammatory
cytokines may be therapeutically beneficial in bronchial
asthma.
Interleukin-10 is a cytokine initially described as an
inhibitor of cytokine synthesis. This molecule is produced
by T helper 2 (Th2) cells, B cells, macrophages, kera-
tinocytes, mast cells and some tumor cells.12–14
Interleukin-10 exhibits anti-inflammatory properties both
in vivo and in vitro by directing Th populations toward a
Th2-like cytokine production profile.15–17 Furthermore, 
IL-10 inhibits the production of Th1 cytokines, such as
IFN-g and IL-2.18–21 In monocyte/macrophage lineage
cells, IL-10 reduces the release of various inflammatory
cytokines, such as IL-1, IL-6, IL-8, GM-CSF and tumor
necrosis factor (TNF)-a .22–25 Thus, IL-10 may be a potent
regulator of allergic inflammation in the pathogenesis of
bronchial asthma. However, there have been no previ-
ous reports of the effects of IL-10 on antigen-induced
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production of inflammatory cytokines in asthmatic
patients in vitro.
In the present study, we examined whether IL-10 could
suppress the production of inflammatory cytokines, such
as GM-CSF, IL-5, IL-2, IL-1 b and IFN-g , by specific
antigen (house dust mite) stimulation in mononuclear
cells (MNC) of asthmatic patients.
METHODS
Subjects
Studies were performed on cells from 30 patients with
bronchial asthma (as defined by the criteria of the
American Thoracic Society) with a mean age of 42.4 ±
6.3 years and seven healthy subjects with a mean age 
of 40.0 ± 7.3 years. The scores of asthmatic patients 
in a radioallergosorbent test (RAST) against Dermatopha-
goides farinae (Df) were > 2 (> 2 is positive on a 0–4
score) and those of healthy subjects against Df were all neg-
ative, as measured with a Phadebas RAST kit (Pharmacia
Diagnostics, Uppsala, Sweden). None of the patients had
received steroid therapy. Peripheral blood was collected
during periods free from asthmatic attacks. All patients gave
their informed consent for participation in the study.
Reagents
The following reagents were used: Df antigen (Torii
Pharmaceutical Co., Tokyo, Japan), recombinant human
IL-10 (ED50 with TF-1 cells, 1 ng/mL; PeproTech Inc.,
Rocky Hill, NJ, USA), monoclonal antihuman IL-10 anti-
body (R & D Systems Inc., Minneapolis, MN, USA).
Recombinant human IL-4 (specific activity 1.0 · 106
U/mg protein) was kindly provided by Ono Pharma-
ceutical Co. (Osaka, Japan). Dermatophagoides farinae
antigen, recombinant human IL-10 and recombinant
human IL-4 used in the present study did not contain
levels of endotoxin detectable by the Limulus test (sensitiv-
ity limit 0.3 ng/mL; Seikagaku Kogyo, Tokyo, Japan).
Isolation of peripheral blood mononuclear
cells
Heparinized peripheral blood samples were obtained
from patients, who had given their informed consent to
participation in the study, and were diluted with an equal
volume of phosphate-buffered saline (PBS). The cells
were centrifuged at 400 · g for 30 min in lymphocyte
separation medium (density at 20°C 1.077–1.080 g/mL;
Organon Teknika Corp., Durham, NC, USA). The cells at
the gradient interface were collected and washed twice in
PBS with centrifugation at 150 · g for 10 min. These cells
were mainly mononuclear cells (96%) and their viability
was > 98%, as determined by the trypan blue dye exclu-
sion test.
Preparation of cell-conditioned media
Mononuclear cells were washed twice with RPMI-1640
(Nissui Pharmaceutical Co., Tokyo, Japan) and resus-
pended in RPMI-1640 supplemented with 10% fetal calf
serum (FCS). They were plated in triplicate at a final con-
centration of 2 · 106 cells/mL, with or without Df antigen
(10 mg/mL, unless otherwise stated), IL-10 (10 ng/mL)
and/or IL-4 (10 ng/mL); 10 mg/mL of Df antigen was
chosen as the optimal concentration based on a previous
report.26 The MNC were then incubated for 3 days at
37°C in an atmosphere of 5% CO2 and 95% humidity in
air. Then, cell-free supernatants were obtained by cen-
trifugation at 150 · g for 10 min and stored at – 70°C
until use.
Measurement of cytokines
Interleukin-5 and GM-CSF were measured with commer-
cial enzyme-linked immunosorbent assay (ELISA) kits
(Quantikine Human Immunoassay; R & D Systems Inc.),
which specifically detected human IL-5 and GM-CSF,
respectively. Interferon-g , IL-1b and IL-2 were measured by
ELISA (Otsuka Pharmaceutical Co., Tokushima, Japan),
which specifically detected human IFN-g , IL-1b and IL-2,
respectively. In these assays, the minimum detectable con-
centrations of human IL-5, GM-CSF, IFN-g , IL-1b and IL-2
were 1.0, 1.5, 20, 8 and 25 pg/mL, respectively.
Statistical analysis
Data are presented as the mean ± SEM. Individual
experimental values were compared by paired two-tailed
Student t-tests. Concentration dependency was examined
by one-way analysis of variance of repeated measure-
ments. A level of P < 0.05 was considered significant.
RESULTS
Inhibitory effect of IL-10 on GM-CSF produc-
tion by blood MNC from asthmatic subjects
The effects of IL-10 on GM-CSF production were exam-
ined in blood MNC of asthmatic patients and healthy
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subjects (Fig. 1). The basal level of GM-CSF production
without Df stimulation was higher in asthmatic patients
than in healthy subjects (56.9 ± 40.7 vs 15.6 ±
6.1 pg/mL, P < 0.05). Although the addition of Df
antigen to the cultures enhanced the production of 
GM-CSF in both groups, the level of the induction 
was much higher in asthmatic patients (143.9 ± 59.4 
vs 56.9 ± 40.7 pg/mL, P < 0.05) than in healthy sub-
jects (54.6 ± 6.5 vs 15.6 ± 6.1 pg/mL, P < 0.05).
Interleukin-10 (10 ng/mL) markedly inhibited the ele-
vated production of GM-CSF by Df stimulation to a level
less than that under unstimulated control conditions in
both asthmatics (5.1 ± 2.4 vs 143.9 ± 59.4 pg/mL, 
P < 0.05) and healthy subjects (3.4 ± 1.0 vs 54.6 ±
6.5 pg/mL, P < 0.05). The inhibition by IL-10 was dose-
dependent and reached the lowest level at 10 ng/mL
IL-10 in three experiments with different asthmatic
patients (Fig. 2 shows representative data from one asth-
matic patient). Because IL-4 is also known as a cytokine
synthesis inhibitory factor, the inhibitory effect of IL-10 on
GM-CSF production was compared with that of IL-4
(Fig. 3). Although IL-4 (10 ng/mL) also inhibited GM-
CSF production by MNC from asthmatic patients in both
the presence and absence of Df antigen, the inhibitory
effect of IL-10 was much stronger (6.3 ± 2.6 vs 134.3
± 79.5 pg/mL, P < 0.05) than that of IL-4 (40.2 ±
17.7 vs 134.3 ± 79.5 pg/mL, P < 0.05).
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Fig. 1 Down-regulatory effect of interleukin (IL)-10 on gran-
ulocyte–macrophage colony stimulating factor (GM-CSF)
production by peripheral mononuclear cells (MNC) from asth-
matic patients (n = 30) and healthy subjects (n = 7). The MNC
were incubated with Dermatophagoides farinae (Df) antigen
(10 m g/mL; j), IL-10 (10 ng/mL; ), both Df and IL-10 ( ) or
medium alone (h) for three days and the concentrations of
GM-CSF in the supernatants were determined by enzyme-
linked immunosorbent assay as described in the Methods
section.
Fig. 2 Dose-dependent effects of interleukin (IL)-10 on gran-
ulocyte–macrophage colony stimulating factor (GM-CSF)
production by peripheral mononuclear cells (MNC) from asth-
matic patients. The MNC were incubated in the presence of
Dermatophagoides farinae (Df) antigen (10 m g/mL) with
various concentrations of IL-10 (0.1–100 ng/mL) for 3 days
and the concentrations of GM-CSF in the supernatants were
determined by enzyme-linked immunosorbent assay as
described in the Methods section. Values are the mean + SEM
from triplicate cultures.
Fig. 3 Comparison of the effects of interleukin (IL)-4 and IL-
10 on granulocyte–macrophage colony stimulating factor
(GM-CSF) production by peripheral mononuclear cells (MNC)
from asthmatic patients (n = 7). The MNC were incubated with
or without Dermatophagoides farinae (Df) antigen (10 m g/mL),
IL-4 (10 ng/mL) and IL-10 (10 ng/mL) for 3 days and the con-
centrations of GM-CSF in the supernatants were determined by
enzyme-linked immunosorbent assay as described in the
Methods section. Values are the mean + SEM from seven
patients.
Inhibitory effect of IL-10 on IL-5 production by
blood MNC from asthmatic subjects
Levels of IL-5 production by MNC without Df stimulation
were low and were not different between asthmatic patients
and healthy subjects (7.1 ± 4.0 vs 1.6 ± 4.0 pg/mL, not
significant (NS)). The Df antigen stimulated the production
of IL-5 by MNC from asthmatic patients at signif-icantly
higher levels (82.5 ± 32.8 vs 7.1 ± 4.0 pg/mL, P < 0.05)
compared with those from healthy subjects (6.0 ± 2.5 vs
1.6 ± 0.3 pg/mL, NS). Under the same experimental con-
ditions, addition of IL-10 (10 ng/mL) resulted in significant
inhibition of IL-5 production by Df-stimulated MNC in
asthmatic patients (1.4 ± 0.3 vs 82.5 ± 32.8 pg/mL, 
P < 0.05, Fig. 4). The inhibitory effect of IL-10 was dose-
dependent and reached the lowest level at 10 ng/mL of
IL-10 in three experiments in different asthmatic patients
(Fig. 5 shows representative data from one asthmatic
patient).
Inhibition of IFN-g , IL-1b and IL-2 production
by IL-10 in asthmatic subjects and healthy
volunteers
We also examined the inhibitory effects of IL-10 on the pro-
duction of IFN-g (Fig. 6), IL-1b (Fig. 7) and IL-2 (Fig. 8).
Interferon-g production was detected in the supernatants of
MNC from both asthmatic patients (192.3 ± 47.3 pg/mL)
and from healthy subjects (256.7 ± 46.7 pg/mL) with-
out Df stimulation. Induction of IFN-g production by 
Df stimulation was not significantly different between the 
two groups (810.9 ± 276.4 vs 192.3 ± 47.3 pg/mL, 
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Fig. 4 Down-regulatory effect of interleukin (IL)-10 on IL-5
production by peripheral mononuclear cells (MNC) from asth-
matic patients (n = 30) and healthy subjects (n = 7). The MNC
were incubated with Dermatophagoides farinae (Df) antigen
(10 m g/mL; j), IL-10 (10 ng/mL; ), both Df and IL-10 ( ) or
medium alone (h) for 3 days and the concentrations of IL-5 
in the supernatants were determined by enzyme-linked
immunosorbent assay as described in the Methods section.
Fig. 5 Dose-dependent effects of interleukin (IL)-10 on IL-5
production by peripheral mononuclear cells (MNC) from an
asthmatic patient. The MNC were incubated in the presence of
Dermatophagoides farinae (Df) antigen (10 m g/mL) with
various concentrations of IL-10 (0.1–100 ng/mL) for 3 days.
The concentrations of IL-5 in the supernatants were determined
by enzyme-linked immunosorbent assay as described in the
Methods section. Values are the mean + SEM from triplicate
cultures.
Fig. 6 Down-regulatory effects of interleukin (IL)-10 on inter-
feron (IFN)-g production by peripheral mononuclear cells
(MNC) from asthmatic patients (n = 30) and healthy subjects 
(n = 7). The MNC were incubated with Dermatophagoides
farinae (Df) antigen (10 m g/mL; j), Df and IL-10 (10 ng/mL;
) or medium alone (h) for 3 days and the concentrations of
IFN-g in the supernatants were determined by enzyme-linked
immunosorbent assay as described in the Methods section.
P < 0.05 and 908.7 ± 196.4 vs 256.7 ± 46.7 pg/mL, 
P < 0.05). In contrast, the stimulatory effect of Df antigen
on IL-1b production in asthmatic patients (289.0 ± 105.0
vs 10.3 ± 1.5 pg/mL, P < 0.05) was stronger than that 
in healthy subjects (110.0 ± 25.8 vs 9.6 ± 1.6 pg/mL, 
P < 0.05). Interleukin-2 was not detected in the super-
natant of MNC from subjects without Df stimulation and
the antigen stimulation of IL-2 production was observed
only in asthmatic patients (61.5 ± 13.7 pg/mL) and not in
healthy subjects. The levels of production of these three
cytokines were completely reduced by the addition of IL-10
to the unstimulated control level.
Blocking effect of anti-IL-10 antibody on IL-10
inhibition of GM-CSF production in an 
asthmatic subject and a healthy volunteer
To assess whether IL-10 inhibition of cytokine production 
by Df-stimulated MNC is mediated by IL-10 itself, we
examined the blocking effect of anti-IL-10 antibody 
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Fig. 7 Down-regulatory effects of interleukin (IL)-10 on IL-1b
production by peripheral mononuclear cells (MNC) from asth-
matic patients (n = 30) and healthy subjects (n = 7). The MNC
were incubated with Dermatophagoides farinae (Df) antigen
(10 m g/mL; j), Df and IL-10 (10 ng/mL; ) or medium alone
(h) for 3 days and the concentrations of IL-1b in the super-
natants were determined by enzyme-linked immunosorbent
assay as described in the Methods section.
Fig. 8 Down-regulatory effects of interleukin (IL)-10 on IL-2
production by peripheral mononuclear cells (MNC) from asth-
matic patients (n = 30) and healthy subjects (n = 7). The MNC
were incubated with Dermatophagoides farinae (Df) antigen
(10 m g/mL; j), Df and IL-10 (10 ng/mL; ) or medium alone
(h) for 3 days and the concentrations of IL-2 in the super-
natants were determined by enzyme-linked immunosorbent
assay as described in the Methods section. Arrows indicate
negative results (i.e. concentrations below 20 pg/mL).
Fig. 9 Blocking effects of anti-
interleukin (IL)-10 antibody (Ab)
on the production of granulocyte–
macrophage colony stimulating
factor (GM-CSF) by peripheral
mononuclear cells (MNC) from
an asthmatic patient or a healthy
subject. The IL-10 was incubated
with anti-IL-10 antibody for 30
min and the mixture was added
in the culture of Dermatopha-
goides farinae (Df)-stimulated
(10 m g/mL) MNC (final concen-
trations of IL-10 and anti-IL-10
antibody were 10 ng/mL and
2 m g/mL, respectively). The con-
centrations of GM-CSF in the
supernatants were determined by
enzyme-linked immunosorbent
assay as described in the Methods
section. Values are the mean
+ SEM from triplicate cultures.
on GM-CSF production by Df-stimulated MNC in the
presence of IL-10 (10 ng/mL). Interleukin-10 was incu-
bated with anti-IL-10 antibody for 30 min and the
mixture was added in the culture of MNC from an asth-
matic patient or a healthy volunteer (final concentration
of anti-IL-10 antibody in the culture was 2 mg/mL).
Results showed that the antibody completely reversed the
suppressive effect of IL-10 on GM-CSF production in
MNC from both the asthmatic patient (Df, 183 ± 2.9;
Df + IL-10, 26.8 ± 0.7; Df + IL-10 + anti-IL-10, 262 ±
12.1 pg/mL; P < 0.05) and the healthy subject (Df, 70.1
± 2.8; Df + IL-10, 4.4 ± 4.4; Df + IL-10 + anti-IL-10,
103 ± 7.1 pg/mL; P < 0.05; Fig. 9). The antibody
increased GM-CSF production in the absence of Df anti-
gen and IL-10 in the culture of MNC from the healthy
subject (none, 10.4 ± 0.5; anti-IL-10, 43.7 ± 3.8; 
P < 0.05) but not the asthmatic patient (none, 39.2 ±
12.3; anti-IL-10, 60.9 ± 3.0; NS).
DISCUSSION
The Df antigen enhanced the production of GM-CSF, 
IFN-g and IL-1b by MNC obtained not only from asthmatic
patients, but also from healthy subjects. These observations
indicated a possible division of stimulatory effects of Df
antigen on cytokine production by MNC into three groups:
1. Levels of IL-5 and IL-2 production were up-regulated
by Df antigen only in asthmatics who were clinically sensi-
tized with the antigen, but not in healthy subjects, as
reported by other investigators.27
2. Production of GM-CSF and IL-1b was up-regulated
by the antigen in both groups, but this effect was stronger
in asthmatic patients than in healthy subjects.
3. The stimulatory effect of Df antigen on the production
of IFN-g was not different between healthy subjects and
asthmatic patients.
These results may be explained by differences in
responsiveness of cytokine-producing cells to Df antigen.
Cells producing GM-CSF, IFN-g and IL-1b may have
been sensitized by Df antigen or may have responded
strongly to the antigen in both atopic patients, such as
asthma patients, and in healthy subjects and IL-5- and 
IL-2-producing cells may have been sensitized by the
antigen or may have responded to the antigen selectively
in atopic patients, but not in healthy subjects. This
hypothesis is consistent with reports that IL-5 and IL-2 are
essential for the mechanism of helper T lymphocyte-mod-
ulated allergic reactions.4–7 Alternatively, Df antigen may
have dual activities of antigen-specific and non-specific
stimulation, although the non-specific stimulatory effect 
of Df antigen was not due to contaminating endotoxin,
because none was detected by Limulus test. Asthmatic-
selective stimulation of the production of IL-5 and IL-2 may
be induced by antigen-specific activity of Df antigen and the
stimulation of IFN-g production in both asthmatic patients
and healthy subjects may be induced by non-specific activity
of the antigen. Moreover, the enhanced production of GM-
CSF and IL-1b may be induced both by specific and
non-specific activities of the antigen. Further investigations
are needed to clarify the mechanism of these effects.
In the present study, we showed that IL-10 strongly
inhibited the production of inflammatory cytokines, such
as GM-CSF, IL-5, IL-1b , IL-2 and IFN-g, by Df antigen-
stimulated blood MNC. Inhibitory effects of IL-10 on the
production of GM-CSF, IFN-g and IL-1b were found in
both asthmatic patients and in healthy subjects.
Interleukin-10 also inhibited the production of IL-5 and
IL-2 induced by Df antigen in asthmatic patients. This
inhibition was confirmed to be due to IL-10 itself by neutral-
ization of the inhibitory effect by anti-IL-10 antibody.
These observations are consistent with reports showing
that IL-10 inhibits the production of pro-inflammatory
cytokines by monocytes/macrophages stimulated with
non-specific factors and the production of IL-5, IL-2 and
IFN-g by T cells.18–21,28 In addition, the present neutral-
izing study showed that anti-IL-10 antibody increased
GM-CSF production in the absence of IL-10 in culture of
MNC from a healthy subject, but not from an asthmatic
patient. This indicates that endogenous production of 
IL-10 in asthmatic patients does not reach a level cap-
able of suppressing the overproduction of inflammatory
cytokines and that the responsiveness to the inhibitory
effect of IL-10 is not affected in asthmatic patients. There
have been several previous reports regarding endo-
genous production of IL-10 in allergic diseases. Koning
et al. have reported that IL-10 mRNA expression by puri-
fied T cells of children with allergic and non-allergic
asthma and children with atopic dermatitis is strongly
decreased compared with that of healthy controls.29
Borish et al. have reported that the bronchial lavage fluid
of asthmatic patients is characterized by diminished con-
centrations of IL-10 compared with that of normal and
non-asthmatic subjects.30 Moreover, the concentrations
of GM-CSF, IL-5, IL-2 and IL-1 b, but not of IFN-g,
have been reported to be higher in asthmatic patients
compared with non-asthmatic controls.9–11 Interestingly,
Grunig et al. have shown that eosinophilic airway inflam-
mation, IL-5 levels in bronchoalveolar lavage fluid and
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numbers of ab T cells in the lung tissues are all height-
ened in IL-10 gene knockout mice compared with
wild-type controls.31 Thus, decreased IL-10 production
may result in a lack of immunosuppression of allergic
inflammation and exogenous IL-10 may have a bio-
logical function as an anti-allergic cytokine. Analysis of
cytokine production by alveolar macrophages of asth-
matic subjects has demonstrated that inhaled corticosteroid
therapy results in the increased expression of IL-10 mRNA
and protein by alveolar macrophages, while the levels 
of macrophage inflammatory protein-1a , IFN- g and
GM-CSF production are decreased after steroid treat-
ment.32 It has been reported previously that IL-10
administration inhibits inflammatory cell accumulation in
the airways of ovalbumin-sensitized mice.33
In summary, the present findings indicate that the
responsiveness to the inhibitory effect of IL-10 on the pro-
duction of inflammatory cytokines is not abrogated in
asthmatic patients. Therefore, regulation of production of
inflammatory cytokines by IL-10 may be useful in the
treatment of bronchial asthma and further investigation
of the roles of IL-10 in airway of asthmatic patients is
required.
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